Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Human Trials Commence Next Year For The First Genetically-Engineered Malaria Vaccine
Walter and Eliza Hall Institute scientists have created a weakened strain of the malaria parasite that will be used as a live vaccine against the disease. The vaccine, developed in collaboration with researchers from the US, Japan and Canada, will be trialled in humans from early next year.
generic viagra online
American Cancer Society Forum To Address Cancer's Economic Impact On The Workforce
The American Cancer Society will host its inaugural Corporate Impact Conference June 18-19 in Chicago to help large corporate employers diminish the impact of cancer on the workforce and help improve workplace productivity. "Companies Changing the Course of Cancer" is designed to guide businesses in potentially lowering health care costs related to cancer and improving their overall bottom line.
News of the day
Poor Attention In Kindergarten Predicts Lower High School Test Scores, UC Davis Researchers Find
As thousands of students nationwide prepare to leave high school, a UC Davis study appearing online in the June issue of the medical journal Pediatrics shows a clear link between attention problems early in school - as early as kindergarten - and lower high school test scores.
Health Insurance

Pluristem Therapeutics Announces First Patient Enrollment In Phase I Clinical Trial For Treatment Of Peripheral Artery Disease With PLX-PAD

Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that the first patient has been enrolled in a Phase I clinical trial of the Company"s allogeneic placental-derived adherent stromal cell product, termed PLX-PAD. PLX-PAD is being used in patients afflicted with critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). The first patient was enrolled at the Franziskus-Krankenhaus Hospital, Berlin. The initiation of this study follows the recent approval of the Company"s Clinical Trial Application (CTA) to begin clinical trials with PLX-PAD by the Paul Ehrlich Institute (PEI), the German competent authority in the European Union. The Phase I study is designed to evaluate the safety of PLX-PAD in patients with CLI. A total of up to fifteen adults with the disease will be included in the trial which is being conducted at the Franziskus-Krankenhaus Hospital and Charitç© - Universitç¤tsmedizin Hospital, Berlin. Zami Aberman, Chairman, President and CEO of Pluristem stated, "We are proud to begin clinical trials with PLX-PAD, a cellular therapeutic product derived from the placenta, the organ intimately involved in the miracle of birth and a ubiquitous of adult stromal cells that are easily obtained without harm to the mother or baby. Additionally, our proprietary three-dimensional mass manufacturing technology allows us to grow cells significantly more efficiently and cost-effectively than cells grown via the labor intensive two-dimensional method which is the industry norm." Pluristem Therapeutics Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009